Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialRussell E. Ware, Robert J. Adams, Alex George et al.|The Lancet|2015Cited by 518
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell AnemiaRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|Blood|2015Cited by 17
S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATESDarla Liles, Ali İrfan Kutlar, Nilesh Shah et al.|HemaSphere|2019Cited by 5
Long‐term biological effects in sickle cell disease: insights from a post‐crizanlizumab studyDarla Liles, Abdullah Kutlar, Nirmish Shah et al.|British Journal of Haematology|2021Cited by 5